James Allison, MD

NON-SENATE ACAD EMERITUS(WOS)

Dr. Allison received a BA with honors from the University of Pennsylvania, and, in 1969, his MD from the University of Rochester. His entire post graduate training was at the University of California Los Angeles (UCLA) and the University of California San Francisco (UCSF). He began his medical career at Kaiser San Rafael in 1974 where he was that groups’ first gastroenterologist. In 1977 he transferred to Kaiser Oakland Medical Center where he was a full-time gastroenterologist and educator (Assistant Program Director – Internal Medicine) and where he devoted the majority of his time to patient care, administration, clinical research and teaching. In 1996 he received the Lowell Beal MD Award “in appreciation of his example of academic excellence combined with warm humanity.” He retired as a clinician from Kaiser in 1998.

After his retirement from Kaiser, Dr. Allison was invited to be a member of the University of California San Francisco (UCSF) faculty and an Emeritus Investigator at Kaiser Permanente’s Division of Research.

He is Clinical Professor of Medicine Emeritus at UCSF and is a member of the Division of Gastroenterology at UCSF and the San Francisco General Hospital. In 2003, he received the Bay Area Chapter of the Crohn’s and Colitis Foundation’s Premier Physician Award, and in 2004, the American Gastroenterological Association‘s (AGA) Distinguished Clinician Award. He is a fellow of the American College of Physicians and of the American Gastroenterological Association.

Dr. Allison is a national and international expert on screening tests for colon cancer. In a publication in The New England Journal of Medicine in 1996, he was the first person in the U.S. to show that the fecal immunochemical test (FIT) was superior to the standard guaiac fecal occult blood test for screening for colorectal cancer. Since 2000 Dr. Allison has been an ad hoc consultant to the Centers for Disease Control, National Cancer Institute and the Agency for Healthcare Research and Quality (AHRQ) on issues concerned with screening for colorectal cancer. Currently he is working with the California Colorectal Cancer Coalition (C4), California and San Francisco Departments of Public Health to increase screening rates in the uninsured/underserved population by instituting a FIT based screening program in clinics served by safety net hospitals. The screening model this group has developed is being exported to other parts of the San Francisco Bay Area and state of California and has support from both the CDC and the American Gastroenterological Association.

In addition to expertise in colorectal cancer screening tests, Dr. Allison has been a dedicated researcher in inflammatory bowel disease (IBD). In 2005 he helped establish an Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis) registry of over 25000 patients at Kaiser’s Division of Research. In the past 7 years, close to 20 peer reviewed publications have been published from information contained in the registry.

Dr. Allison’s screening and IBD research has been published in the Annals of Internal Medicine, The New England Journal of Medicine, Gastroenterology, Clinical Gastroenterology and Hepatology, the Journal of the National Cancer Institute and other peer reviewed journals. He has been quoted in Prevention Magazine, the Ladies’ Home Journal, the Wall Street Journal, the San Francisco Chronicle and the New York Times.
Education
PGY 3 and Fellowship in Gastroenterology, 06/1974 - Internal Medicine/Gastroenterology, UCSF
PGY 1&2, 05/1971 - Internal Medicine, UCLA
MD, 05/1969 - Medicine, University of Rochester
AB, 05/1964 - French, University of Pennsylvania
Honors and Awards
  • 2017 Achievement Award, American Cancer Society, 2017
  • Distinguished Clinician Award, American Gastroenterological Association (AGA), 2004
  • Crohn’s and Colitis Foundation’s Premier Physician Award, Bay Area Chapter Crohn's and Colitis Foundation, 2003
  • Lowell Beal MD Award, Kaiser Oakland Medical Center, 1996
Publications
  1. Hoffman RM, Levy BT, Allison JE. Rising Use of Multitarget Stool DNA Testing for Colorectal Cancer. 2021. PMID: 34473264


  2. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. 2018. PMID: 30361511


  3. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. 2018. PMID: 30297909


  4. Liang PS, Allison J, Ladabaum U, Martinez ME, Murphy CC, Schoen RE, Shaukat A, Tinmouth J, Gupta S. Potential intended and unintended consequences of recommending initiation of colorectal cancer screening at age 45 years. 2018. PMID: 30138614


  5. Alsayid M, Singh MH, Issaka R, Laleau V, Day L, Lee J, Allison J, Somsouk M. Yield of Colonoscopy After a Positive Result From a Fecal Immunochemical Test OC-Light. 2018. PMID: 29660528


  6. Dominitz JA, Robertson DJ, Ahnen DJ, Allison JE, Antonelli M, Boardman KD, Ciarleglio M, Del Curto BJ, Huang GD, Imperiale TF, Larson MF, Lieberman D, O'Connor T, O'Leary TJ, Peduzzi P, Provenzale D, Shaukat A, Sultan S, Voorhees A, Wallace R, Guarino PD. Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design. Volume 112 of Issue 11. 2017. PMID: 29016565


  7. Akram A, Juang D, Bustamante R, Liu L, Earles A, Ho SB, Wang-Rodriguez J, Allison JE, Gupta S. Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting. Volume 15 of Issue 8. 2017. PMID: 28167157


  8. Young GP, Senore C, Mandel JS, Allison JE, Atkin WS, Benamouzig R, Bossuyt PM, Silva MD, Guittet L, Halloran SP, Haug U, Hoff G, Itzkowitz SH, Leja M, Levin B, Meijer GA, O'Morain CA, Parry S, Rabeneck L, Rozen P, Saito H, Schoen RE, Seaman HE, Steele RJ, Sung JJ, Winawer SJ. Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer. Volume 122 of Issue 6. 2016. PMID: 26828588


  9. Fraser CG, Allison JE, Young GP, Halloran SP, Seaman HE. Improving the reporting of evaluations of faecal immunochemical tests for haemoglobin: the FITTER standard and checklist. Volume 24 of Issue 1. 2015. PMID: 24584197


  10. Young GP, Symonds EL, Allison JE, Cole SR, Fraser CG, Halloran SP, Kuipers EJ, Seaman HE. Advances in Fecal Occult Blood Tests: the FIT revolution. Volume 60 of Issue 3. 2014. PMID: 25492500


  11. Green BB, Coronado GD, Devoe JE, Allison J. Navigating the murky waters of colorectal cancer screening and health reform. Volume 104 of Issue 6. 2014. PMID: 24825195


  12. Gupta S, Sussman DA, Doubeni CA, Anderson DS, Day L, Deshpande AR, Elmunzer BJ, Laiyemo AO, Mendez J, Somsouk M, Allison J, Bhuket T, Geng Z, Green BB, Itzkowitz SH, Martinez ME. Challenges and possible solutions to colorectal cancer screening for the underserved. Volume 106 of Issue 4. 2014. PMID: 24681602


  13. Fraser CG, Allison JE, Young GP, Halloran SP, Seaman H. A standard for Faecal Immunochemical TesTs for haemoglobin evaluation reporting (FITTER). Volume 51 of Issue Pt 2. 2013. PMID: 24345727


  14. Day LW, Bhuket T, Allison J. FIT testing: an overview. Volume 15 of Issue 11. 2013. PMID: 24218070


  15. Fraser CG, Halloran SP, Allison JE, Young GP. Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT). Volume 51 of Issue 11. 2013. PMID: 23787468


  16. Li D, Collins B, Velayos FS, Liu L, Lewis JD, Allison JE, Flowers NT, Hutfless S, Abramson O, Herrinton LJ. Racial and ethnic differences in health care utilization and outcomes among ulcerative colitis patients in an integrated health-care organization. Volume 59 of Issue 2. 2013. PMID: 24173809


  17. Fraser CG, Allison JE, Young GP, Halloran SP. Quantitation of hemoglobin improves fecal immunochemical tests for noninvasive screening. Volume 11 of Issue 7. 2013. PMID: 23591278


  18. Gupta S, Tong L, Anderson P, Rose B, Carter E, Koch M, Argenbright K, Ahn C, Allison J, Skinner CS. Measurement of colorectal cancer test use with medical claims data in a safety-net health system. Volume 345 of Issue 2. 2013. PMID: 22814361


  19. Allison JE. Colorectal-cancer screening. Volume 366 of Issue 22. 2012. PMID: 22646640


  20. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Volume 143 of Issue 2. 2012. PMID: 22609382


  21. Fraser CG, Allison JE, Halloran SP, Young GP. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. Volume 104 of Issue 11. 2012. PMID: 22472305


  22. Fraser CG, Allison JE, Young GP, Halloran SP. Newer fecal tests: opportunities for professionals in laboratory medicine. Volume 58 of Issue 6. 2012. PMID: 22452971


  23. Allison JE, Fraser CG, Halloran SP, Young GP. Comparing fecal immunochemical tests: improved standardization is needed. Volume 142 of Issue 3. 2012. PMID: 22281273


  24. Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Volume 106 of Issue 12. 2011. PMID: 22031357


  25. Velayos FS, Liu L, Lewis JD, Allison JE, Flowers N, Hutfless S, Abramson O, Perry GS, Herrinton LJ. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Volume 139 of Issue 5. 2010. PMID: 20659470


  26. Abramson O, Durant M, Mow W, Finley A, Kodali P, Wong A, Tavares V, McCroskey E, Liu L, Lewis JD, Allison JE, Flowers N, Hutfless S, Velayos FS, Perry GS, Cannon R, Herrinton LJ. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. Volume 157 of Issue 2. 2010. PMID: 20400099


  27. Allison JE. Colorectal cancer screening guidelines: the importance of evidence and transparency. Volume 138 of Issue 5. 2010. PMID: 20211181


  28. Allison JE. The best screening test for colorectal cancer is the one that gets done well. Volume 71 of Issue 2. 2010. PMID: 20152313


  29. Allison JE, Potter MB. New screening guidelines for colorectal cancer: a practical guide for the primary care physician. Volume 36 of Issue 3. 2009. PMID: 19616156


  30. Gupta S, Tong L, Allison JE, Carter E, Koch M, Rockey DC, Anderson P, Ahn C, Argenbright K, Skinner CS. Screening for colorectal cancer in a safety-net health care system: access to care is critical and has implications for screening policy. Volume 18 of Issue 9. 2009. PMID: 19745221


  31. Herrinton LJ, Liu L, Fireman B, Lewis JD, Allison JE, Flowers N, Hutfless S, Velayos FS, Abramson O, Altschuler A, Perry GS. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Volume 137 of Issue 2. 2009. PMID: 19445944


  32. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Volume 149 of Issue 7. 2008. PMID: 18838724


  33. Allison J, Herrinton LJ, Liu L, Yu J, Lowder J. Natural history of severe ulcerative colitis in a community-based health plan. Volume 6 of Issue 9. 2008. PMID: 18774533


  34. Pressman AR, Hutfless S, Velayos F, Fireman B, Lewis JD, Allison J, Abramson O, Herrinton LJ. Patterns of infliximab use among Crohn's disease patients in a community setting. Volume 14 of Issue 9. 2008. PMID: 18452199


  35. Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Volume 103 of Issue 8. 2008. PMID: 18796097


  36. Altschuler A, Collins B, Lewis JD, Velayos F, Allison JE, Hutfless S, Liu L, Herrinton LJ. Gastroenterologists' attitudes and self-reported practices regarding inflammatory bowel disease. Volume 14 of Issue 7. 2008. PMID: 18300277


  37. Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Volume 133 of Issue 6. 2007. PMID: 18054550


  38. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. Volume 99 of Issue 19. 2007. PMID: 17895475


  39. Allison JE. Should recommendations for colorectal-cancer screening be changed? Volume 4 of Issue 7. 2007. PMID: 17519918


  40. Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization. Volume 102 of Issue 7. 2007. PMID: 17437504


  41. Herrinton LJ, Liu L, Lafata JE, Allison JE, Andrade SE, Korner EJ, Chan KA, Platt R, Hiatt D, O'Connor S. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Volume 13 of Issue 4. 2007. PMID: 17219403


  42. Allison JE, Lawson M. Screening tests for colorectal cancer: a menu of options remains relevant. Volume 8 of Issue 6. 2006. PMID: 17040627


  43. Allison JE. Immunochemical fecal occult blood tests for colorectal cancer screening. Volume 116 of Issue 7. 2004. PMID: 15047043